Results 51 to 60 of about 12,579 (242)

Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles [PDF]

, 2011
Background: There is renewed interest in the development of poxvirus vector-based HIV vaccines due to the protective effect observed with repeated recombinant canarypox priming with gp120 boosting in the recent Thai placebo-controlled trial.
Anson, Donald S., Blanchard, Thomas, Blanchard, Tom J., Bridge, Simon H., Dennis, Mike J., Dowall, Stuart D., Getty, Brian, Sharpe, Sally A., Skinner, Michael A., Stewart, James P.   +9 more
core   +4 more sources

Modified Vaccinia Virus Ankara Encoding Influenza Virus Hemagglutinin Induces Heterosubtypic Immunity in Macaques [PDF]

Journal of Virology, 2014
ABSTRACT Current influenza virus vaccines primarily aim to induce neutralizing antibodies (NAbs). Modified vaccinia virus Ankara (MVA) is a safe and well-characterized vector for inducing both antibody and cellular immunity. We evaluated the immunogenicity and protective efficacy of MVA encoding influenza virus hemagglutinin (HA)
Kelsey R. Florek, Jason T. Weinfurter, Sinthujan Jegaskanda, Joseph N. Brewoo, Tim D. Powell, Ginger R. Young, Subash C. Das, Masato Hatta, Karl W. Broman, Olav Hungnes, Susanne G. Dudman, Yoshihiro Kawaoka, Stephen J. Kent, Dan T. Stinchcomb, Jorge E. Osorio, Thomas C. Friedrich   +15 more
openaire   +2 more sources

Modified Vaccinia Virus Ankara Immunization Protects against Lethal Challenge with Recombinant Vaccinia Virus Expressing Murine Interleukin-4 [PDF]

Journal of Virology, 2004
ABSTRACT Recent events have raised concern over the use of pathogens, including variola virus, as biological weapons. Vaccination with Dryvax is associated with serious side effects and is contraindicated for many people, and the development of a safer effective smallpox vaccine is necessary.
Lewis H, McCurdy, John A, Rutigliano, Teresa R, Johnson, Man, Chen, Barney S, Graham   +4 more
openaire   +2 more sources

Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial [PDF]

, 2018
BackgroundModified Vaccinia Ankara (MVA) is a live, viral vaccine under advanced development as a non-replicating smallpox vaccine. A randomised, double-blind, placebo-controlled phase III clinical trial was conducted to demonstrate the humoral ...
Chaplin, Paul, De Carli, Sonja, Kreusel, Christian, Lawrence, Steven J, Meyer, Thomas P, Nopora, Katrin, Overton, Edgar Turner, Rosch, Siegfried, Samy, Nathaly, Schnidt, Darja, Wagner, Eva, Weidenthaler, Heinz, Young, Philip   +12 more
core   +3 more sources

Vaccinia protein C16 blocks innate immune sensing of DNA by binding the Ku complex [PDF]

, 2011
VACV gene C16L encodes a 37-kDa protein that is highly conserved in orthopoxviruses and functions as an immunomodulator. Intranasal infection of mice with a virus lacking C16L (vΔC16) induced less weight loss, fewer signs of illness and increased ...
Peters, Nicholas Edward, Peters, Nicholas Edward   +1 more
core   +1 more source

Does limited virucidal activity of biocides include duck hepatitis B virucidal action? [PDF]

, 2012
BACKGROUND: There is agreement that the infectivity assay with the duck hepatitis B virus (DHBV) is a suitable surrogate test to validate disinfectants for hepatitis B virucidal activity.
Bust, Uwe, Glück, Brigitte, Rabenau, Holger, Sauerbrei, Andreas, Schacke, Michael, Wutzler, Peter   +5 more
core   +1 more source

Prevention of infection and disruption of the pathogen transfer chain in elective surgery [PDF]

, 2020
The COVID-19 pandemic has caused us all to stop our normal activities and consider how we can safely return to caring for our patients. There are many common practices (such as an increased use of personal protective equipment) which we are all familiar ...
Chisari, Emanuele, Krueger, Chad A., Lowry Barnes, C., Parvizi, Javad, Van Onsem, Stefaan, Walter, William   +5 more
core   +2 more sources

Shaping the tumor microenvironment with Modified Vaccinia Virus Ankara and TLR9 ligand [PDF]

OncoImmunology, 2015
Our preclinical data demonstrate that an intravenous injection of Modified Vaccinia virus Ankara induces CD8+ lymphocytes to infiltrate organs to control the growth of orthotopic renal carcinoma upon combination with a toll-like receptor 9 agonist.
Préville, Xavier, Rittner, Karola, Fend, Laetitia   +2 more
openaire   +2 more sources

Vaccinia virus immune evasion: mechanisms, virulence and immunogenicity [PDF]

, 2013
Virus infection of mammalian cells is sensed by pattern recognition receptors and leads to an innate immune response that restricts virus replication and induces adaptive immunity.
Benfield, C T O, De Motes, C M, Ember, S W J, Ferguson, B J, Mazzon, M, Smith, G L, Sumner, R P   +6 more
core   +1 more source

Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara

Expert Review of Vaccines, 2009
Recombinant modified vaccinia virus Ankara (MVA) is attractive and promising as a novel viral vector for the expression of foreign genes of interest because it possesses unique properties. In particular, its excellent safety profile and the availability of versatile vector technologies have frequently made MVA the vaccinia virus of choice for ...
Rimmelzwaan, Guus, Sutter, G
openaire   +2 more sources